Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clidinium is a synthetic anticholinergic agent used primarily to treat gastrointestinal disorders such as peptic ulcer disease, irritable bowel syndrome (IBS), colicky abdominal pain, and diverticulitis. It acts by inhibiting the muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites, with a primary effect on M1 muscarinic receptors. This results in reduced gastric acid secretion and decreased gastrointestinal motility and spasms. Clidinium is often formulated in combination with chlordiazepoxide (a benzodiazepine) for enhanced therapeutic effect in conditions involving both anxiety and GI spasm[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clidinium.